Article Text

Download PDFPDF
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Addendum On 12 February 2020, NICE approved ▼sotagliflozin for use with insulin for people with type 1 diabetes with BMI ≥27 kg/m2. The issues raised in this editorial also apply to the use of sotagliflozin.